T1	Participants 374 445	patients with locally advanced or metastatic non-small-cell lung cancer
T2	Participants 455 542	1692 patients who were refractory to or intolerant of their latest chemotherapy regimen
T3	Participants 942 995	1129 patients were assigned gefitinib and 563 placebo
